Statin use and venous thromboembolism recurrence: A combined nationwide cohort and nested case-control study

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 8, 2014, Pages 1207-1215

  Schmidt, M ^a   Cannegieter, S C ^b   Johannesdottir, S A ^a   Dekkers, O M ^b   Horvath Puho E ^a   Sorensen H T ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Hydroxymethylglutaryl CoA reductase inhibitors; Prognosis; Recurrence; Venous thromboembolism

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG POTENCY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; VALIDATION STUDY; DENMARK; VENOUS THROMBOEMBOLISM;

CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECURRENCE; VENOUS THROMBOEMBOLISM;

EID: 84905695597     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12604     Document Type: Article

References (38)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-8.
2. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 2010; 170: 1710-6.
3. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013; 347: f5133.
4. Squizzato A, Galli M, Romualdi E, Dentali F, Kamphuisen PW, Guasti L, Venco A, Ageno W. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010; 31: 1248-56.
5. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, Robertson M, Wikstrand J, McMurray J. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012; 9: e1001310.
6. Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulant effects of statins and their clinical implications. Thromb Haemost 2014; 111: 392-400.
7. Delluc A, Tromeur C, Le Moigne E, Nowak E, Mottier D, Le Gal G, Lacut K. Lipid lowering drugs and the risk of recurrent venous thromboembolism. Thromb Res 2012; 130: 859-63.
8. Biere-Rafi S, Hutten BA, Squizzato A, Ageno W, Souverein PC, de Boer A, Gerdes VEA, Büller HR, Kamphuisen PW. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 2013; 34: 1800-6.
9. Nguyen CD, Andersson C, Jensen TB, Gjesing A, Schjerning Olsen A-M, Malta Hansen C, Büller H, Torp-Pedersen C, Gislason GH. Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study. BMJ Open 2013; 3: e003135.
10. Johannesdottir SA, Horvath-Puho E, Ehrenstein V, Schmidt M, Pedersen L, Sørensen HT. Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 2012; 4: 303-13.
11. Institute for rational pharmacotherapy. Guidelines for statin treatment in Denmark. Available at: http://www.irf.dk/dk/redskaber/faq/spoergsmaal_og_svar_om_statinbehandling.htm#indikation. Accessed 28 August 2013.
12. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39: 22-5.
13. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39: 30-3.
14. Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjønneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol 2010; 63: 223-8.
15. Guidelines for treatment of deep venous thrombosis in Denmark [In Danish]. Available at www.laegehaandbogen.dk. Accessed 1 March 2013.
16. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005; 162: 975-82.
17. Johannesdottir SA, Schmidt M, Horvath-Puho E, Sørensen HT. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2012; 10: 815-21.
18. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
19. O'Connell RL, Lim LL. Utility of the Charlson comorbidity index computed from routinely collected hospital discharge diagnosis codes. Methods Inf Med 2000; 39: 7-11.
20. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
21. Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 2006; 44: 1075-82.
22. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2008.
23. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96.
24. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161: 1405-10.
25. Ramcharan AS, van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJM. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009; 7: 514-20.
26. Sørensen HT, Horvath-Puho E, Søgaard KK, Christensen S, Johnsen SP, Thomsen RW, Prandoni P, Baron JA. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009; 7: 521-8.
27. Glynn RJ, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-61.
28. Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2011; 128: 422-30.
29. Zolcinski M, Ciesla-Dul M, Undas A. Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost 2012; 107: 1180-2.
30. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 2002; 53: 375-8.
31. Zalfani J, Frøslev T, Olsen M, Ben Ghezala I, Gammelager H, Arendt JF, Erichsen R. Positive predictive value of the International Classification of Diseases, 10th edition diagnosis codes for anemia caused by bleeding in the Danish National Registry of Patients. Clin Epidemiol 2012; 4: 327-31.
32. Lassen A, Hallas J, de Muckadell OBS. Complicated and Uncomplicated Peptic Ulcers in a Danish County 1993-2002: A Population-Based Cohort Study. Am J Gastroenterol 2006; 101: 945-53.
33. Krarup L-H, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007; 28: 150-4.
34. Doggen CJM, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970-5.
35. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, Griffin JH. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007; 115: 1609-14.
36. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, Solomon DH. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166: 348-54.
37. Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 2012; 175: 250-62.
38. Thomsen RW, Nielsen RB, Nørgaard M, Horsdal HT, Til S, Larsen FB, Sørensen HT. Lifestyle profile among statin users. Epidemiology 2013; 24: 619-20.